PND16 Economic Evaluation of Pregabalin and Gabapentin for Neuropathic Pain from the Brazilian Public Health Care System Perspective  by Mould, J.F. et al.
tor, emergency department (ED), or “other,” as well as the number of CD-related
hospital admission days. Unit costs were assigned to each type of health care
resource using national non-Medicare 2011 reimbursement rates. Hospitalization
cost was estimated using the HCUP.net mean daily cost of inpatient stay (principal
diagnosis 333.83). Cost of an ED visit was estimated by the mean paid amount for
ED visit (principal diagnosis 333.83) using commercial claims data. RESULTS: Base-
line data were available for 786 participants at time of analysis. The mean age was
57.7 years, and the majority (76%) were female. The mean (SD) number of visits to
a primary care providerwas 1.4 (2.1), 1.9 (1.9) for neurologist, 0.7 (1.8) for physiatrist,
1.8 (3.8) for physical/occupational therapy, 0.2 (0.9) for neurosurgeon, 1.3 (3.1) for
alternative care provider, 1.1 (3) for chiropractor, and 3.2 (2.7) for “other.” Partici-
pants reported amean(SD) of 0.2(0.9) visits to the ED and 0.1(0.6) hospital admission
days. The mean total cost of CD over 6 months was $1,255.80 (range $0-$63,320.20;
median $639.80). The largest single cost driver was the number of hospital admis-
sion days. CONCLUSIONS: The economic impact of CD-related health care re-
source use should not be overlooked when assessing disease burden.
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OBJECTIVES: The economic burden of Multiple Sclerosis (MS) on society and the
individuals concerned is not known. Documenting such costs is essential for sev-
eral reasons: costs of illness is a key factor of optimal diseasemanagement policies,
knowledge of cost is useful for allocating research anddevelopment. The aimof our
study as the first pharmacoeconomic investigation in Iran was to estimate the
costs of multiple sclerosis according to severity of disease.METHODS: Total, direct
and indirect costs were compared in 160 patients divided into three groups cate-
gorized by disease severity: stage I Expanded Disability Status Scale (EDSS 2.5),
stage II (EDSS 3- 4.5) and stage III (EDSS 5).The majority of these patients (94%)
developed relapsing- remitting MS.A minority of the patients (0.2-4 %) developed
secondary progressive and primary progressive MS. Cost evaluation was per-
formed from the societal perspective and covered the one-year period. The study
was carried out at the Division of Neurology at GhaemHospital andMS association
in Mashhad in northeast of Iran and was approved by the local ethics committee.
RESULTS: The mean total cost/patient for one year was estimated at $27,095,
$27,997and $31,662 for stage I, II and III, respectively. Both direct and indirect costs
increased with MS progression. For indirect cost the main item was productivity
loss. Themean extramedicine (treatments forMS symptoms and adverse effects of
medications) cost/patient for one year was calculated at $19,036. CONCLUSIONS:
This study confirms that MS represents a high economic burden to patients and
society, with direct costs greatly exceeding indirect costs. As costs increase with
disease progression, treatment efforts should focus on patients in the early stages
of MS. Disease support system that monitors a variety of common progressive
signs for the MS individuals is a key element of a management program as well.
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OBJECTIVES: Seizure control through antiepileptic drugs (AEDs) is integral to treat-
ment of Lennox-Gastaut syndrome (LGS). Although six AEDs are approved for LGS
(clobazammost recently, October 2011), no standard treatment paradigm has been
established. Understanding the economic burden associated with LGS is critical to
developing such guidance. The objective of this study was to examine health care
resource utilization and costs for patients with LGS.METHODS:Medical and phar-
macy claims data (1/1/2007–9/30/2010) from a large US managed health care plan
affiliated with OptumInsight were analyzed. Study patients were those with evi-
dence of LGS based on 2medical claims (30 days apart) with diagnosis (ICD-9-CM)
of generalized, nonconvulsive (or convulsive) epilepsy. Evidence of developmental
diagnoses and 12 months of continuous health plan enrollment following initial
epilepsy diagnosis were required. Health care resource utilization and costs were
examined during a 12-month follow-up period and computed separately as all-
cause, epilepsy-related (i.e., any epilepsy care), or related to seizure-attributable
events (e.g., lacerations, fractures). RESULTS: A total of 1,948 patients with evi-
dence of LGS were identified; demographics were consistent with published sur-
veys. Mean counts of epilepsy-related health care visits at 12 months were 10.73
(all-cause: 33.97) for ambulatory visits and 0.75 (all-cause: 0.86) for inpatient ad-
missions. Mean epilepsy-related health care cost was $29,911 (all-cause: $44,797),
of which the greatest components were inpatient costs (epilepsy-related: $18,119;
all-cause: $19,590) and ambulatory costs (epilepsy-related: $5,515; all-cause: $11,907).
Meanmedical cost related to seizure-attributable eventswas$13,038.CONCLUSIONS:
A high economic burden was observed in this LGS sample, with frequent health
care visits and high costs attributable to epilepsy care. Nearly one-third of total
medical costs were associated with seizure-attributable events, highlighting the
need for effective seizure control. These results will be useful for understanding
the budgetary impact and cost effectiveness of AED therapy in LGS treatment.
PND14
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OBJECTIVES: The majority of epileptic patients manage their condition with anti-
epileptic drugs (AEDs) to prevent seizures. Despite being adherent to AEDs, some
patients fail to have adequate seizure control; therefore, they have refractory epi-
lepsy. This study assessed the health care costs and resource utilization of epilepsy
patients with partial onset seizures (POS) who were refractory compared to non-
refractory patients.METHODS:Administrative claims from 2004-2008 in a US com-
mercially insured population were analyzed. Patients aged 18-64 years were se-
lected if they had medical claims with POS (ICD-9-CM codes: 345.4, 345.5). This
study used an operational definition of 3 different AED agents dispensed as refrac-
toriness. Patients were considered refractory from the year they received the third
AED and forward. Annual direct health care utilization and costs within each cal-
endar year among patients who were continuously enrolled were compared be-
tween refractory and non-refractory cohorts. RESULTS: The study identified 79,149
patients with POS (mean age 33 years; 54.8% female), and 8,714 (11%) patients
became refractory. In 2008, refractory patients were more likely to have a hospital
admission (27.2% vs. 16.9%; p0.001). Average annual health care costs for refrac-
tory patients were significantly higher than non-refractory patients ($33,613 vs.
$19,085; p0.001), as well as by settings for inpatient ($11,780 vs. $6,076; p0.001),
outpatient ($12,677 vs. $8,125; p0.001) and pharmacy costs ($5,280 vs. $2,256;
(p0.001). Close to half of total costs were attributable to POS-related services.
Similar trends were observed when assessing POS-related costs and utilization.
The differences were consistent across calendar years examined. CONCLUSIONS:
The findings from this study suggest refractoriness in epilepsy patients with POS is
associated with high economic burden from the health insurer’s perspective. Re-
fractory patients incurred 76%more healthcare costs than non-refractory patients.
Improving seizure control and reducing the economic burden of refractory epilepsy
remain important unmet medical needs in this population.
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OBJECTIVES: This study estimated health care resource utilization (HCRU) and
medical costs in both pediatric and adult Medicaid populations, comparing epilep-
sy-related costs with overall costs. METHODS: A retrospective analysis was con-
ducted using Thomson Reuters’ Medicaid claims data from 13 states (2005-2009).
Epilepsy patients were identified through ICD-9 code 345.xx and 780.39. Annual
HCRU and medical costs (in 2009 dollars) in adult (18 years) and pediatric pa-
tients (2-17 years) were estimated separately. HCRU was considered as epilepsy-
related if it was associated with ICD-9 code of 345.xx or 780.39, or was an anti-
epileptic drug. RESULTS: A total of 75,111 patients were identified with epilepsy,
with 31,484 pediatric (mean age 8.8 years) and 43,627 adult (mean age 40.4 years).
Annually, a pediatric patient with epilepsy incurred 0.23 hospital admissions (0.13
epilepsy-related), 1.31 ER visits (0.38 epilepsy-related), 6.12 physician office visits
(1.25 epilepsy-related), 3.25 outpatient hospital visits (0.91 epilepsy-related), 27.17
other outpatient visits (1.62 epilepsy-related), 22.3 prescriptions (3.96 epilepsy-re-
lated). Among adult patients, average HCRU was 0.90 hospital admissions (0.43
epilepsy-related), 3.52 ER visits (0.66 epilepsy-related), 10.26 physician office visits
(1.62 epilepsy-related), 7.44 outpatient hospital visits (1.07 epilepsy-related), 58.69
other outpatient visits (2.65 epilepsy-related), 71.43 prescriptions (10.1 epilepsy-
related). Direct medical costs per patient were $10,669 (18.4% epilepsy-related) for
a pediatric patient and $29,886 (17.7% epilepsy-related) for an adult patient. Overall
directmedical costs associated with active epilepsy in the identifiedMedicaid pop-
ulation were $293 million ($62 million for pediatric and $231 million for adult).
CONCLUSIONS: Non-epilepsy related HCRU and direct medical costs dominated
HCRU and direct medical costs in Medicaid patients with epilepsy, indicating that
substantial comorbidities are associated with epilepsy patients in the Medicaid
population. Adult patients had higher HCRU and direct medical costs compared to
pediatric patients, which may be related to likely differences in the types of epi-
lepsy experienced by children and adults.
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OBJECTIVES: Based on the work of Sicras-Mainar et al. 2011, evaluating real world
data on the resource consumption of patients treated with pregabalin and gabap-
entin for neuropatic pain, an adaptation to the Brazilian public health care system
was carried in order to compare both strategies. METHODS: A cost-minimization
study was designed considering the length of treatment, daily dose strengths dis-
tributions, hospitalization days, medical visits, physiotherapy sessions and other
concomitant medications used. Frequencies and resource use was obtained from
the aforementioned study, and prices were retrieved from national databases
(Banco de Preços em Saúde and SIGTAP - Sistema de Gerenciamento da Tabela de
Procedimentos, Medicamentos e OPM do SUS). To best represent the values for the
not-normal distribution of length of treatment frequencies reported in the study, a
Monte Carlo simulation using 10.000 iterationswas carried considering a triangular
distribution. The timehorizonwas defined as 1 year. Valueswere expressed in 2011
USD. RESULTS:The overall costs ofmedications compared in this study per patient
were 332.74 and 291.20 USD for pregabalin and gabapentin, respectively. Health
care utilization costs were 89.12 and 128.76 USD for pregabalin and gabapentin
treated patients respectively. Other concomitant medication costs were 56.29 and
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94.78 USD for pregabalin and gabapentin per patient respectively. Total costs per
treatment were 478.15 and 514.73 USD for pregabalin and gabapentin treatments
respectively, representing a cost-saving per patient of 36.58 USD for pregabalin.
CONCLUSIONS: Pregabalin is a cost-saving option compared to gabapentin, repre-
senting a treatment that diminishes the health care system resource utilization
while shortening patient’s length of treatment and reducing the burden related to
other concomitant medications used.
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OBJECTIVES: To model the value of screening for early Parkinson’s Disease (PD). A
model to evaluate lifetime economic value from slowing progression over the
course of PD was adapted to assess sequential olfactory testing and dopamine
transporter (DAT) imaging for screening for pre-motor disease in different patient
groups. METHODS: Data from the PD Associated Risk Study (PARS) were used to
parameterize the model. We assessed screening in patients aged 55 with varying
risk: a general population; persons with a relative with PD; persons with LRRK2
genotype; and persons with REM sleep disorder. PD prevalence per 100,000 at
screeningwas 5, 20, 100 and 200 for these groups. Olfactory test andDAT costswere
$15 and $2500.We assumed that diseasemodifying (DM) therapywas available that
slowed disease progression by 20% at a cost of $35,000. Economic value was mea-
sured in terms of netmonetary benefit (NMB), valuing quality-adjusted life-years at
$50,000. RESULTS: Of those who took the olfactory test, 13.4% yielded positive
results and also took the DAT. The sensitivity and specificity of screeningwere 64%
and 99%. NMB for the four groups was -$211, $217, $2,495, and $5,344, indicating
that screening has positive economic value in personswith a close relativewith PD,
persons with LRRK2 genotype, and persons with REM sleep disorder. Screening
value was positively correlated with rate of progression from preclinical to clinical
PD, efficacy of DM therapy, and preclinical health utility. Screening value was
negatively correlatedwith costs of false positives or false negatives, screening cost,
age at preclinical onset, age at unscreened diagnosis, Hoehn and Yahr stage at
which the unscreened diagnosis is made, and cost of DM therapy. CONCLUSIONS:
Under certain scenarios, particularly in high risk groups, screening for early PD
may be a cost effective strategy.
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OBJECTIVES: To perform a cost-effectiveness analysis of Fingolimod 0.5mg for
Relapsing-RemittingMultiple Sclerosis versus first line treatment options available
in the Public Health Care System in México. METHODS: A Markov model was de-
signed to analyze the cost-effectiveness of Fingolimod vs Glatiramer Acetate and
Interferon- (IFN). The model identifies 5 health-states based on the Expanded
Disability Status Scale. A systematic review was performed to obtain transition
probabilities used in the model. Clinical data for Fingolimod comes from twomain
studies, FREEDOMS and TRANSFORMS, with around 2,186 patients analyzed. Fin-
golimod showed a reduction annualized relapsed rate with fingolimod was signif-
icantly lower (0.18 and 0.20) versus its comparators with placebo and interferones
(0.40 and 0.33). Cycle duration was 1 month, and time horizon 10 years with a
discount rate of 5%. Efficacy was evaluated by QALYs using utility data from inter-
national literature. Directmedical costs include the number of relapses expected in
each of the treatments. Relapses cost are valuated according to the event severity
identified in the DRGs List published by the Mexican Institute of Social Security.
Drug costs are those from public tenders 2011. (US$1MX$13.8). Probabilistic sen-
sitivity analysis (PSA) was performed using Monte Carlo technique. RESULTS: The
expected 10–year costs and QALYs per patient with each treatment were: Fingoli-
mod US$337,994/5.62; IFN-1a6MU US$428,689/1.64; IFN-1a12MU US$468,958/
1.59; IFN-1b8MU US$493,690/1.49; Glatiramer Acetate US$526,444/1.65. PSA
showed Fingolimod was dominant or below the Mexican threshold of 1 PIB per
cápita ( US$8,586) vs all comparators, 85% of the times. Robustness in the results
were confirmed though the sensitivity analysis. CONCLUSIONS: For patients with
Relapsing-Remitting Multiple Sclerosis, treatment with oral Fingolimod is an effi-
cacious and cost-saving option compared with current available options in the
health system. The higher drug acquisition cost of Fingolimod is compensated by
its lower rate of relapse and disability progression.
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OBJECTIVES: Patientswith refractory seizures have highermorbidity andmortality
rates, and poorer quality of life scores, than those with controlled seizures. To
select an adequate therapy aimed to control seizures, decision must be based not
only clinical criteria but also in cost-effectiveness evidence. The objective of this
study is to analyze the cost-effectiveness of lacosamide 200 & 400 mg/d compared
to lamotrigine 300 mg/d and topiramate 200 mg/d as adjunctive therapies for pa-
tientswith uncontrolled partial-onset seizures in Colombia from the health system
perspective. METHODS: An Excel-based, tree-decision model was developed to
assess the cost-effectiveness of the compared therapies. Treatment efficacy was
measured using the proportion of individual with a 50% or greater reduction in
seizure frequency from baseline to maintenance period. Other model parameters
and adverse events rates were extracted from randomized clinical trials identified
through a systematic literature review. Placebo adjustment was performed and
horizon was established as the titration period plus maintenance of 12-weeks.
Direct costs associated with medication, adverse events and cost related to treat-
ment failure were considered. Medications costs were extracted from the 4316-
2011 legislation and procedures’ cost were obtained from the SOAT -2011 formu-
lary. Cost effectiveness ratios were calculated and deterministic sensitivity
analysis was conducted. RESULTS: Higher rates of responders were reported in
lacosamide-400mg(39%) followed by lacosamide-200mg (33%), topiramate-200mg
(31%) and lamotrigine-300mg (24%). Mean cost per patient was lower in lam-
otrigine-300mg and lacosamide-200mg groups, ($668USD;$669USD respectively),
followed by topiramate-200mg ($689USD) and lacosamide-400mg ($818USD). The
cost-effectiveness ratio per responder was favorable for lacosamide-200mg and
lacosamide-400mg ($2.057USD-$2086USD) followed by topiramate-200mg and
lamotrigine-300mg ($2.228USD and $2748USD). The ICER for lacosamide-400mg
was in all cases less than $100USD/additional responder. CONCLUSIONS: The eco-
nomic model demonstrated that lacosamide-200mg and lacosamide-400mg are
cost-effective treatments compared to lamotrigine-300mg and topiramate-200mg
in patients whit uncontrolled partial-onset seizures in Colombia.
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Parkinson’s disease (PD) is a neurodegenerative disease with a variety of clinical
manifestations because of neuronal lost. Formany years levodopahas beenused to
improve dopamine concentrations at the brain; however after a period of benefit,
different limitations appearwith levodopa use, includingmotor complications that
can affect patients’ quality of life. Delaying the use for levodopa and the onset of
motor complications is really important. OBJECTIVES: To compare the cost-effec-
tivenes from a Mexican setting of the use of rasagiline monotherapy vs the use of
pramipexole as treatment strategies in early PD. METHODS: We developed an
economic Markov model to compare information on the effectiveness, utility and
costs of the use of rasagiline and pramipexol over a 5 year period with six-month
cicles. Model input data were obtained fromHaycox et al model and validated in an
expert panel of Mexican Neurologists. Epidemiologic information was obtained
from Mexican Health Minister. The expert panel was developed with a Delphi
method to validate resource utilization, costs and utility of the disease. Costs were
obtained from the Mexican Social Security Institute public lists. Effectiveness out-
comes were time to levodopa, time to levodopa-induced dyskinesia and QALYs.
RESULTS:Rasagilinewas the dominant strategy. Evidence from themodel suggests
that in comparation with pramipexol, early use of rasagiline is associatied with a
healt gain reflected in prolonged time to initiate levodopa by 23.57% through a gain
of 0.796 levodopa-free years; delay in dyskinesia onset by 11.8% (0.49 years); and a
5.4% gain in QALY over a 5- year period. The cost per QALY by year found was MxP
33.400,00 wich is less than a Mexican GDP. Sensivity analyses confirmed that the
model was robust. CONCLUSIONS: The model demostrates that rasagiline is a
cost-effective alternative to pramipexol in the treatment of early PD in Mexico.
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COST-EFFECTIVENESS ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE
TREATMENT OF LENNOX-GASTAUT SYNDROME
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OBJECTIVES: Effective seizure control is integral to treatment of Lennox-Gastaut
syndrome (LGS), a debilitating form of epilepsy characterized by developmental
disorders and frequent drop attacks. In an indirect comparison of antiepileptic
drugs (AEDs) FDA-approved for LGS, clobazam was associated with the greatest
effect size for decreasing drop attacks. We developed an economic model to eval-
uate outcomes and costs of clobazam, from a payer perspective, vs. lamotrigine,
rufinamide, and topiramate as adjunctive therapy for LGS. METHODS: Baseline
seizure frequency (132/month) and AED efficacy were modeled through clinical
trial data. Costs of treating drop seizures were derived from a study of administra-
tive claims data from a large USmanaged health care plan affiliatedwith OptumIn-
sight, with the assumption that 2.3% of drop seizures led to medical care. Seizure
frequency and percentage of patients free of drop seizures were evaluated over a
3-month horizon. Clobazam and rufinamide were also evaluated over 2 years (as-
sumption: 128 seizures/month at baseline). Sensitivity analyses were performed.
RESULTS: Results suggest that LGS patients receiving clobazam had 226 drop sei-
zures over 3 months, compared with 261, 275, and 281 for rufinamide, topiramate,
and lamotrigine, respectively. More than 21% of patients receiving clobazam were
free of drop seizures after 3 months, vs. 5% in each comparator group. Drug and
medical costs for patients receiving clobazam totaled $29,000, vs. $32,000–33,000
for comparators. Clobazam was also more efficacious and less costly than rufin-
amide over a 2-year horizon. Alternative analyses with assumptions of lower rates
of seizures upon discontinuation did not alter conclusions. Assumption that fewer
drop seizures require medical care (0.5% vs. 2.3%) reduced the short-term but not
the long-term cost effectiveness of clobazam. CONCLUSIONS: Medically attended
drop seizures are a major cost driver in LGS. For these LGS patients, clobazammay
be cost-saving.
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